1.Establishment of a novel canine model of severe acute cholangitis
Zhong CHEN ; Lirong ZHU ; Cunwang GE
Chinese Journal of General Surgery 2001;0(08):-
Objective To establish a novel canine model of severe acute cholangitis(ACST).Methods Ten dogs were randomly divided into two groups:model group and control group.ACST models were established by placing T-tube in common bile duct and ligating the distal bile duct,then injecting E.coli trough T-tube and closing the T-tube.The changes of peripheral WBC,total bilirubin,ALT,AKP,IL-1?,TNF-? and endotoxin were observed pre-operatively and at 24 h,48 h,72 h,and 7 d post-operatively.The pathological changes of bile duct were observed when the dogs were sacrificed.Results There were no significant differences in all indices between two groups pre-operatively.Serum IL-1?,TNF-?,endotoxin and total bilirubin,ALT,AKP level in model group increased gradually and were higher than control group(P
2.New progression of translational research on colorectal cancer.
Shu ZHENG ; Weiting GE ; Jiekai YU ; Qi DONG ; Jianwei WANG ; Lirong CHEN
Chinese Journal of Gastrointestinal Surgery 2016;19(6):601-606
Precision medicine is becoming the goal of translational research on colorectal cancer. Accurate molecular subtyping contributes to better guidance of clinical practice. The current TNM staging system of colorectal cancer is inadequate in terms of guiding clinical practice, such as the underestimation of prognosis of with stage II( and III( colorectal cancer TNM staging, and identification of high-risk and low-risk patients with stage II( colorectal cancer. Researchers from Europe and US have proposed a number of molecular subtypings with clinicopathological phenotypes and molecular phenotypes, which has certain practical significance and is beneficial to the choice of treatment regimen and targeted drugs. But the current results of subtyping research require further validations by clinical large scale multi-center trials. Based on precision medicine, molecular subtyping gradually reveals its clinical significance and is optimized through combining genomics with various clinical phenotypes, indicating its guidance for clinical practice, which is the inevitable course of precision medicine accomplishment. In recent years, there have been many new advances in colorectal cancer liver metastasis treatment. The prognosis of colorectal cancer patients undergoing resection of liver metastasis lesion is similar to those with stage III(. Early recurrence within 6 months after translational treatment and resection occurred in about one third of the patients with initially unresectable liver metastasis, and the overall survival was poor. Thus, an evaluation system should be established in order to avoid the strong therapy and strive for better quality of life in some patients. Individualized treatment for colorectal cancer is emphasized increasingly. Body fluid (peripheral blood and urine) marker detection is a recent research hotspot, including serum protein(polypeptide), plasma miRNA, circulating tumor cells and circulating nucleic acid.
Biomarkers, Tumor
;
blood
;
urine
;
Colorectal Neoplasms
;
diagnosis
;
pathology
;
therapy
;
Humans
;
Liver Neoplasms
;
secondary
;
Neoplasm Recurrence, Local
;
Neoplasm Staging
;
Precision Medicine
;
Prognosis
;
Quality of Life
;
Translational Medical Research
3.Advances in the biosynthesis of L-homoserine and its derivatives by metabolic engineering of Escherichia coli.
Kun NIU ; Liping GAO ; Lirong GE ; Zhiqiang LIU ; Yuguo ZHENG
Chinese Journal of Biotechnology 2022;38(12):4385-4402
L-homoserine and its derivatives (O-succinyl-L-homoserine and O-acetyl-L-homoserine) are precursors for the biosynthesis of L-methionine, and various C4 compounds (isobutanol, γ-butyrolactone, 1, 4-butanediol, 2, 4-dihydroxybutyric acid) and L-phosphinothricin. Therefore, the fermentative production of L-homoserine and its derivatives became the research hotspot in recent years. However, the low fermentation yield and conversion rate, and the unclear regulation mechanism for the biosynthesis of L-homoserine and its derivatives, hamper the development of an efficient production process for L-homoserine and its derivatives. This review summarized the advances in the biosynthesis of L-homoserine and its derivatives by metabolic engineering of Escherichia coli from the aspects of substrate uptake, redirection of carbon flow at the key nodes, recycle of NADPH and export of target products. This review may facilitate subsequent metabolic engineering and biotechnological production of L-homoserine and its derivatives.
Escherichia coli/metabolism*
;
Metabolic Engineering
;
Homoserine/metabolism*
;
Escherichia coli Proteins/metabolism*
;
Fermentation
4.Interpretation of presynaptic dopaminergic PET imaging results
Ping WU ; Jianjun WU ; Xun SUN ; Jingjie GE ; Fangyang JIAO ; Chengfeng JIANG ; Lirong JIN ; Xinlu WANG ; Zhenguang WANG ; Yafu YIN ; Ruixue CUI ; Rong TIAN ; Shuo HU ; Rongbing JIN ; Jianjun LIU ; Xiangsong ZHANG ; Ling CHEN ; Jie LU ; Xingmin HAN ; Yihui GUAN ; Xiaoli LAN ; Chuantao ZUO ; Jian WANG
Chinese Journal of Nuclear Medicine and Molecular Imaging 2023;43(4):236-241
Presynaptic dopaminergic PET imaging is a useful method for the diagnosis of parkinsonism. Based on the expert consensus on operation and clinical application of dopamine transporter brain PET imaging technology published in 2020, this paper further recommends the relevant elements of result interpretation of presynaptic dopaminergic PET imaging.
5.Intensive phototherapy vs. exchange transfusion for the treatment of neonatal hyperbilirubinemia: a multicenter retrospective cohort study.
Meng ZHANG ; Yang HE ; Jun TANG ; Wenbin DONG ; Yong ZHANG ; Benjin ZHANG ; Hong WAN ; Quanmin DENG ; Lirong GUAN ; Bin XIA ; Zhong CHEN ; Min GE ; Jing ZHAO ; Wenxing LI ; Jingjun PEI ; Yi QU ; Dezhi MU
Chinese Medical Journal 2022;135(5):598-605
BACKGROUND:
Intensive phototherapy (IPT) and exchange transfusion (ET) are the main treatments for extreme hyperbilirubinemia. However, there is no reliable evidence on determining the thresholds for these treatments. This multicenter study compared the effectiveness and complications of IPT and ET in the treatment of extreme hyperbilirubinemia.
METHODS:
This retrospective cohort study was conducted in seven centers from January 2015 to January 2018. Patients with extreme hyperbilirubinemia that met the criteria of ET were included. Patients were divided into three subgroups (low-, medium-, and high- risk) according to gestational week and risk factors. Propensity score matching (PSM) was performed to balance the data before treatment. Study outcomes included the development of bilirubin encephalopathy, duration of hospitalization, expenses, and complications. Mortality, auditory complications, seizures, enamel dysplasia, ocular motility disorders, athetosis, motor, and language development were evaluated during follow-up at age of 3 years.
RESULTS:
A total of 1164 patients were included in this study. After PSM, 296 patients in the IPT only group and 296 patients in the IPT plus ET group were further divided into the low-, medium-, and high-risk subgroups with 188, 364, and 40 matched patients, respectively. No significant differences were found between the IPT only and IPT plus ET groups in terms of morbidity, complications, and sequelae. Hospitalization duration and expenses were lower in the low- and medium-risk subgroups in the IPT only group.
CONCLUSIONS
In this study, our results suggest that IPT is a safe and effective treatment for extreme hyperbilirubinemia. The indication of ET for patients with hyperbilirubinemia could be stricter. However, it is necessary to have a contingency plan for emergency ET as soon as IPT is commenced especially for infants with risk factors. If IPT can be guaranteed and proved to be therapeutic, ET should be avoided as much as possible.
Child, Preschool
;
Exchange Transfusion, Whole Blood/adverse effects*
;
Humans
;
Hyperbilirubinemia, Neonatal/therapy*
;
Infant
;
Infant, Newborn
;
Kernicterus/therapy*
;
Phototherapy/methods*
;
Retrospective Studies